The change of the fingolimod patient profile over time: a comparison of two non-interventional studies PANGAEA and PANGAEA 2.0.

被引：0
|
作者：
Cornelissen, C. [1 ]
Ziemssen, T. [2 ]
机构：
[1] Novartis Pharma GmbH, Nurnberg, Germany
[2] Univ Klinikum Carl Gustav Carus, Zentrum Klin Neurowissensch, Dresden, Germany
来源：
EUROPEAN JOURNAL OF NEUROLOGY | 2018年 / 25卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
EPR3107
引用
收藏
页码：538 / 538
页数：1
相关论文
共 36 条
  • [1] The fingolimod patient profile 2011 and 2017: a comparison of two non-interventional studies PANGAEA and PANGAEA 2.0
    Cornelissen, C.
    Kern, R.
    Ziemssen, T.
    MULTIPLE SCLEROSIS JOURNAL, 2017, 23 : 595 - 596
  • [2] The Change of Fingolimod Patient Profiles over Time: A Descriptive Analysis of Two Non-Interventional Studies PANGAEA and PANGAEA 2.0
    Ziemssen, Tjalf
    Schulze-Topphoff, Ulf
    JOURNAL OF PERSONALIZED MEDICINE, 2021, 11 (06):
  • [3] Fingolimod 2012 and 2016: How did the profile of patients treated with fingolimod change? A comparison of two non-interventional studies PANGAEA and PANGAEA 2.0
    Cornelissen, C.
    Kern, R.
    Ziemssen, T.
    EUROPEAN JOURNAL OF NEUROLOGY, 2017, 24 : 196 - 196
  • [4] Study design of PANGAEA 2.0, a non-interventional study on RRMS patients to be switched to fingolimod
    Tjalf Ziemssen
    Raimar Kern
    Christian Cornelissen
    BMC Neurology, 16
  • [5] Study design of PANGAEA 2.0, a non-interventional study on RRMS patients to be switched to fingolimod
    Ziemssen, Tjalf
    Kern, Raimar
    Cornelissen, Christian
    BMC NEUROLOGY, 2016, 16
  • [6] Patients switching to fingolimod in daily clinical routine: 2 year interim results from the non-interventional study PANGAEA 2.0
    Schulze-Topphoff, U.
    Ettle, B.
    Cornelissen, C.
    Ziemssen, T.
    MULTIPLE SCLEROSIS JOURNAL, 2018, 24 : 932 - 932
  • [7] 5 years effectiveness of fingolimod in daily clinical practice: results of the non-interventional study PANGAEA
    Ziemssen, T.
    Albrecht, H.
    Haas, J.
    Klotz, L.
    Lang, M.
    Lassek, C.
    Schmidt, S.
    Tackenberg, B.
    Cornelissen, C.
    MULTIPLE SCLEROSIS JOURNAL, 2017, 23 : 372 - 373
  • [8] PANGAEA: the average German fingolimod patient. Demographics and baseline characteristics from a 5 year non-interventional study of RRMS patients treated with fingolimod
    Ziemssen, T.
    Albrecht, H.
    Haas, J.
    Klotz, L.
    Lang, M.
    Lassek, C.
    Schmidt, S.
    Tackenberg, B.
    Cornelissen, C.
    MULTIPLE SCLEROSIS JOURNAL, 2015, 21 : 695 - 695
  • [9] PANGAEA: The average German fingolimod patient. Demographics and baseline characteristics from a 5 year non-interventional study of RRMS patients treated with fingolimod
    Ziemssen, T.
    Albrecht, H.
    Klotz, L.
    Schmidt, S.
    Schwarz, H-J
    Tackenberg, B.
    Cornelissen, C.
    EUROPEAN JOURNAL OF NEUROLOGY, 2015, 22 : 620 - 620
  • [10] 4 years PANGAEA: effectiveness update of a 5 year non-interventional study on the daily use of fingolimod in Germany
    Ziemssen, T.
    Albrecht, H.
    Haas, J.
    Klotz, L.
    Lang, M.
    Lassek, C.
    Schmidt, S.
    Tackenberg, B.
    Cornelissen, C.
    MULTIPLE SCLEROSIS JOURNAL, 2016, 22 : 642 - 643
1234